Search results
Results from the WOW.Com Content Network
Dextran and oxidized dextran can be used to crosslink gelatin microspheres to reduce gelatin dissolution, which slows the drug release rate. These dextran/gelatin microspheres can be used to provide slow-release of TRAPP-Br, which is a cancer therapeutic. [8]
Dextran is used to make microcarriers for industrial cell culture; Orally-administered dextran sodium sulphate is used to induce colitis in animal models of inflammatory bowel disease. [12] Dextran is a common model compound to test the potential of drug formulations to facilitate intestinal absorption via the paracellular route. [13]
Hydroxyethyl starch (HES/HAES), sold under the brand name Voluven among others, is a nonionic starch derivative, used as a volume expander in intravenous therapy.The use of HES on critically ill patients is associated with an increased risk of death and kidney problems.
Cancer treatments are a wide range of treatments available for the many different types of cancer, with each cancer type needing its own specific treatment. [1] Treatments can include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy including small-molecule drugs or monoclonal antibodies, [2] and PARP inhibitors such as olaparib. [3]
MHC multimers may also be used to eliminate harmful or unwanted T-cells in vivo, such as those that target self cells and lead to autoimmune disease. [4] [5] [6] Cancer immunotherapy and vaccine development can also be largely influenced by this technology. [7]
A professor with the University of Texas at San Antonio has created a new method to kill cancer cells that are traditionally difficult to eradicate. New cancer treatment method causes cells to ...
Dextran sulphate sodium (DSS), or dextran sodium sulphate (or any of the former with "sulfate") is a synthetic sulphated polysaccharide with anticoagulant activity used in immunological research to induce colitis. [1] [2] Dextran polymer molecules with a molecular weight of 36–50 kDa are frequently used to this end. [2]
In 1992 it was removed from the market and manufacturing ceased. During this time low molecular weight iron dextran was introduced and released for clinical use in 1992. [4] The use of low molecule weight iron dextran was common place for renal dialysis patients and due to its success usage increased progressively through to 1997. [4]